The global market for pain management devices is anticipated to rise over the course of the forecast period as chronic, neurological, and musculoskeletal ailments become more prevalent everywhere. Patients with long-term, neurological, and musculoskeletal diseases can use pain management devices to treat both acute and chronic pain. These tools lessen the need for oral painkillers, assist in regaining daily function, and enhance the quality of life for patients with these illnesses. The major causes of death and disability in the United States, according to the Centers for Disease Control and Prevention (CDC), are chronic diseases like diabetes, cancer, and heart disease. During the course of the projected period, an increase in the worldwide elderly population is anticipated to boost market growth for pain management devices. Players in the pain management market should benefit from tremendous growth potential due to the rising demand for novel pain management devices and medicines.
Coherent Market Insights estimates that According to forecasts, the market for Pain Management Devices will grow at a CAGR of 6.54% between 2022 and 2028, from a value of US$ 3,771.46 Mn in 2021 to US$ 5,767.69 Mn by 2028.
Prominent Companies in the Pain Management Industry:
1. B. Braun Melsungen AG
The company is headquartered in Melsungen, Germany, and was established in 1839. In addition to other healthcare goods and services, the company offers extracorporeal blood therapies, anaesthesia, emergency care, and surgical core procedures. Intermedt Medizin & Technik GmbH, a pioneer in the development of dialysis concentrates, was acquired by B. Braun in March 2022. With the groundbreaking of a new factory in January 2022, B. Braun expanded its footprint in Vietnam.
2. Medtronic Plc
The company is headquartered in Dublin, Ireland, and was established in 1949. Medical diagnostic and therapeutic products are produced by Medtronic, PLC. In April 2022, the company declared that it would collaborate with GE Healthcare to address the care needs at ambulatory surgery centres. The purchase of Affera, Inc. was announced by the business in January 2022. In January 2020, the company declared its intention to acquire Stimgenics, LLC and their primary treatment.
3. Pfizer Inc.,
The corporation was founded in 1849, and its corporate headquarters are located in Manhattan, New York City. Pfizer works to advance the disciplines of immunology, cancer, the heart, endocrinology, and neurology through pharmaceutical and vaccine research & development. The company successfully purchased the calcitonin gene-related peptide programmes from Biohaven Pharma in October 2022. In April 2021, Pfizer acquired Amplyx Pharmaceuticals, along with the antifungal medication fosmanogepix. (APX001).
